Overview

A Safety Study in Participants With Advanced Solid Tumors

Status:
Terminated
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cisplatin
Dacarbazine
Docetaxel
Erlotinib Hydrochloride
Gemcitabine
Temozolomide